Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for inhibiting Aβ production in HEK293 cells stably overexpressing amyloid precursor protein (APP).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $52 | In Stock | |
| 10 mg | $97 | In Stock | |
| 25 mg | $178 | In Stock | |
| 50 mg | Preferential | In Stock | |
| 1 mL x 10 mM (in DMSO) | $59 | In Stock |
| Description | BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for inhibiting Aβ production in HEK293 cells stably overexpressing amyloid precursor protein (APP). |
| Targets&IC50 | β-Amyloid (HEK293 cells):7 nM, β-Amyloid (HEK293 cells):7 nM |
| In vitro | BMS-299897 (1 μM) decreases these peptides to levels ranging from 20 to 50% of the vehicle control. Furthermore, it leads to a reduction in the proportion of QD-BDNF signals moving in the retrograde direction (p=0.0198) while concurrently increasing the proportion of signals moving in the anterograde direction (p=0.0147).[2] |
| In vivo | BMS-299897 (0.1-1 nmol/mouse; male Swiss mice; one week) blocks the increase in Aβ1-42 content and decreases Aβ1-40 levels significantly. The compound does not affect the Aβ25-35-induced increase in hippocampal lipid peroxidation. Behaviorally, BMS-299897 blocks the Aβ25-35-induced deficits in spontaneous alternation or novel object recognition, using a 1 h intertrial time interval. The co-administration of the γ-secretase inhibitor BMS-299897, in the 0.1-1 μmol/mouse dose range, completely blocks the Aβ25-35-induced increase in Aβ1-42 content.[1] |
| Molecular Weight | 511.94 |
| Formula | C24H21ClF3NO4S |
| Cas No. | 290315-45-6 |
| Smiles | C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O |
| Relative Density. | 1.421 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27 mg/mL (52.74 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.91 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.